What is cagrilintide?

• What cagrilintide is, and why it is an amylin analog rather than a GLP-1
• How amylin engages brainstem satiety circuits distinct from GLP-1
• Why CagriSema combines cagrilintide with semaglutide, and what the REDEFINE trials showed
• Its investigational status, the safety profile, and the honest limits of the evidence

1. 01 What is cagrilintide? The second hormone in the next obesity drug free
2. 02 The amylin hormone The forgotten twin of insulin paid
3. 03 How cagrilintide works The brainstem switch for fullness paid
4. 04 Why combine two hormones Two appetite brakes are better than one paid
5. 05 The REDEFINE trials From a dose-finding trial to phase 3 paid
6. 06 Chemistry & pharmacokinetics The fatty tail that makes it weekly paid
7. 07 The obesity drug landscape Where CagriSema sits in a crowded field paid
8. 08 Safety & Side Effects Mostly the gut, with class warnings to watch paid
9. 09 Dosing & Administration The trial schedule, and why you cannot buy it paid
10. 10 Regulatory & market landscape A drug the market is watching, not yet selling paid
11. 11 Final Exam & Certification Pass the final exam to earn your specialist certificate. exam

Cagrilintide is a long-acting copy of amylin, a hormone your pancreas releases alongside insulin after you eat. Amylin is one of the body's natural "I am full" signals: it tells the brain to end the meal, slows the stomach, and steadies blood sugar. Cagrilintide is engineered to do the same job, but to last a full week instead of minutes.

The engineering is what makes cagrilintide a drug rather than a curiosity. Natural amylin is destroyed in minutes and tends to clump into harmful fibrils; cagrilintide is redesigned to resist both problems and to hitch a ride on blood albumin so it circulates for days. That is why it works as a once-weekly injection where the older amylin drug required three shots a day.

The most common mistake is to lump cagrilintide in with Ozempic and Wegovy. Those are GLP-1 drugs; cagrilintide is an amylin drug. They are both appetite hormones and both cause weight loss, but they act on different receptors in different brain circuits, which is the entire reason they are worth combining.

Because they use separate receptors and partly separate brain regions, their effects can add together rather than simply overlap. That complementarity is the scientific bet behind CagriSema: two appetite brakes are stronger than one. Calling cagrilintide "a GLP-1" erases the very distinction that makes the combination interesting.

Cagrilintide can be used alone, but its fame comes from CagriSema, its combination with semaglutide in a single weekly injection. Because semaglutide is already a blockbuster GLP-1 drug, stacking a second appetite hormone on top of it drew enormous scientific and market attention.

The design goal is simple to state and hard to prove: deliver more weight loss than semaglutide alone by adding the amylin arm, without stacking up intolerable side effects. As later units show, the phase 3 REDEFINE trials confirmed the extra weight loss is real, though the size of the added benefit became a genuine point of debate.

Neither cagrilintide nor CagriSema is approved by any drug regulator as of 2026. They are investigational: studied in large trials, heading toward regulatory submission, but not yet a product you can be prescribed or legally buy. This status has real consequences that separate CagriSema from Wegovy or Mounjaro.

The practical upshot is stark: the only legitimate source of cagrilintide today is a Novo Nordisk clinical trial. Because it has never been an approved drug and is not on the FDA drug-shortage list, it is not legally compoundable either, which makes any "research peptide" cagrilintide sold online unregulated and unverified. Investigational is not a technicality; it defines what you can and cannot responsibly say about the drug.

Cagrilintide sits in an unusual spot: it has genuinely strong trial evidence for a drug that is not yet approved, alongside real gaps that its GLP-1 competitors have already filled. Keeping those apart is the job of this course, and the place to start is an honest map of what is and is not established.

Hold these four tiers in mind for the rest of the course. The weight-loss efficacy is genuinely solid, the mechanism is well-understood, but the "strongest drug ever" framing and the long-term outcome questions sit in the weak-to-missing tiers. Honest education names that structure instead of rounding CagriSema up to a finished breakthrough.